Treatment-free survival (TFS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with 1L nivolumab plus ipilimumab (NIVO plus IPI) or platinum doublet chemotherapy (PDC) in CheckMate (CM) 227

被引：1
|
作者：
Peters, S. [1 ]
Penrod, J. [2 ]
Li, J. [2 ]
Lubinga, S. [2 ]
Gupta, R. [2 ]
Bushong, J. [2 ]
Rizzo, J. [2 ]
Ramalingam, S. [3 ]
机构：
[1] Lausanne Univ Hosp, Dept Oncol UNIL CHUV, Lausanne, Switzerland
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] Emory, Winship Canc Inst, Atlanta, GA USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10P
引用
收藏
页码：S32 / S33
页数：2
相关论文
共 50 条
  • [41] Real-world (RW) outcomes in metastatic renal cell carcinoma (mRCC) patients treated with first-line (1L) nivolumab plus ipilimumab (NIVO plus IPI) in the United States
    Geynisman, D.
    Chan, P.
    Robert, N.
    Chen, L.
    Del Tejo, V.
    Rosenblatt, L. C.
    Huo, S.
    Doshi, G.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1216 - S1216
  • [42] MIXTURE-CURE MODELLING OF THE OVERALL SURVIVAL OUTCOMES OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) RECEIVING NIVOLUMAB plus IPILIMUMAB IN CHECKMATE-227
    Young, R.
    Pritchard, C.
    Yuan, Y.
    Chaudhary, M.
    Lee, A.
    Gordon, J.
    McEwan, P.
    VALUE IN HEALTH, 2022, 25 (07) : S531 - S531
  • [43] Clinical outcomes in patients (pts) with tumor PD-L1 < 1% with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) vs chemo alone for metastatic NSCLC (mNSCLC): Results from CheckMate 9LA
    John, T.
    Ciuleanu, T-E.
    Cobo Dols, M.
    Schenker, M.
    Zurawski, B.
    Menezes, J.
    Richardet, E. A.
    Bennouna, J.
    Cheng, Y.
    Felip, E.
    Juan Vidal, O. J.
    Alexandru, A.
    Paz-Ares, L.
    Lu, S.
    Reck, M.
    Hu, N.
    Zhang, X.
    Grootendorst, D. J.
    Eccles, L.
    Carbone, D. P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1034 - S1034
  • [44] Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1
    Makoto Nishio
    Yuichiro Ohe
    Satoshi Ikeda
    Toshihide Yokoyama
    Hidetoshi Hayashi
    Tatsuro Fukuhara
    Yuki Sato
    Hiroshi Tanaka
    Katsuyuki Hotta
    Shunichi Sugawara
    Haruko Daga
    Isamu Okamoto
    Kazuo Kasahara
    Tateaki Naito
    Li Li
    Ravi G. Gupta
    Judith Bushong
    Hideaki Mizutani
    International Journal of Clinical Oncology, 2023, 28 (10) : 1369 - 1370
  • [45] Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line (1L) Treatment (tx) of Advanced Nsclc: Overall Survival (Os) Analysis of Checkmate 817
    Fischer, Juergen R.
    Barlesi, Fabrice
    Audigier-Valette, Larisse
    Felip, Enriqueta
    Ciuleanu, Tudor-Eliade
    Jao, Kevin
    Rijavec, Erika
    Urban, Laszlo
    Aucoin, Jean-Sebastien
    Zannori, Cristina
    Vermaelen, Karim
    Aren Frontera, Osvaldo
    Ready, Neal
    Fontecedro, Alessandra Curioni
    Linardou, Helena
    Poddubskaya, Elena
    Pillai, Rathi
    Li, Sunney
    Acevedo, Angelic
    Paz-Ares, Luis
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 236 - 236
  • [46] First-line (1L) nivolumab (N) plus ipilimumab (I) with 2 cycles of platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): Results from an interim analysis of the German non-interventional study (NIS) FINN
    Kuon, J. B.
    Von der Heyde, E.
    Sadjadian, P.
    Bischoff, M.
    Hassler, A.
    Althoff, A.
    Wilop, S.
    Behringer, D. M.
    Blau, W.
    Huebner, G.
    Flieger, D.
    Ziske, C.
    Groschek, M.
    Laack, H-E.
    Mueller-Huesmann, H.
    Schumann, C.
    Waldenberger, D.
    Guetz, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S852 - S852
  • [47] Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.
    McDermott, David F.
    Rini, Brian I.
    Motzer, Robert J.
    Tannir, Nizar M.
    Escudier, Bernard
    Kollmannsberger, Christian K.
    Hammers, Hans J.
    Porta, Camillo
    George, Saby
    Donskov, Frede
    Gurney, Howard
    Grimm, Marc-Oliver
    Harrison, Michael Roger
    Hutson, Thomas E.
    Yang, Shuo
    Johansen, Jennifer
    Rao, Sumati
    Mekan, Sabeen Fatima
    Rael, Michael
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [48] First-line (1L) nivolumab (N) plus ipilimumab (I) with two cycles of chemotherapy (chemo) in patients with metastatic non-small cell lung cancer (mNSCLC): Results from an interim analysis of the non-interventional FINN study
    Kuon, Jonas
    von der Heyde, Eyck
    Bischoff, Marina
    Wilop, Stefan
    Behringer, Dirk
    Blau, Wolfgang
    Huebner, Gerdt
    Flieger, Dimitri
    Forstbauer, Helmut
    Groschek, Matthias
    Laack, Heinz-Eckart
    Mueller-Huesmann, Harald
    Schumann, Christian
    Waldenberger, Daniela
    Guetz, Sylvia
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 132 - 132
  • [49] Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer
    Reck, Martin
    De, Tuli
    Paz-Ares, Luis
    Edmondson-Jones, Mark
    Yuan, Yong
    Yates, Georgia
    Zoffoli, Roberto
    Chaudhary, Mohammad Ashraf
    Lee, Adam
    Varol, Nebibe
    Penrod, John R.
    CLINICAL LUNG CANCER, 2024, 25 (07) : e362 - e368
  • [50] First-line nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC): Results from an interim analysis of the non-interventional FINN study
    Kuon, J. B.
    von der Heyde, E.
    Wilop, S.
    Behringer, D. M.
    Blau, W.
    Huebner, G.
    Flieger, D.
    Forstbauer, H.
    Groschek, M.
    Laack, H-E.
    Mueller-Huesmann, H.
    Schumann, C.
    Waldenberger, D.
    Guetz, S.
    ANNALS OF ONCOLOGY, 2023, 34
12345